HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.0
  1. Home
  2. /Reaction

Hexylene Glycol → (s)-Tert-butyl 4-((e)-8-chlorodibenzo[b,f][1,4]oxazepin-11-yl)-2-(2-((r)-4-hydroxy-4-methylpentan-2-yloxy)-2-oxoethyl)piperazine-1-carboxylate

HRID 417823
Notes
Print preview

Reaction equation

HRID 417823 reaction equation
[C:1]([O:5][C:6]([N:8]1[CH2:13][CH2:12][N:11]([C:14]2=[N:15][C:16]3[CH:28]=[C:27]([Cl:29])[CH:26]=[CH:25][C:17]=3[O:18][C:19]3[CH:24]=[CH:23][CH:22]=[CH:21][C:20]2=3)[CH2:10][C@@H:9]1[CH2:30][C:31]([OH:33])=[O:32])=[O:7])([CH3:4])([CH3:3])[CH3:2].Cl.CN(C)CCCN=C=NCC.[CH3:46][CH:47](O)[CH2:48][C:49]([OH:52])([CH3:51])[CH3:50]>CN(C=O)C.CN(C)C1C=CN=CC=1>[Cl:29][C:27]1[CH:26]=[CH:25][C:17]2[O:18][C:19]3[CH:24]=[CH:23][CH:22]=[CH:21][C:20]=3[C:14]([N:11]3[CH2:12][CH2:13][N:8]([C:6]([O:5][C:1]([CH3:4])([CH3:2])[CH3:3])=[O:7])[C@@H:9]([CH2:30][C:31]([O:33][C@@H:47]([CH2:48][C:49]([OH:52])([CH3:51])[CH3:50])[CH3:46])=[O:32])[CH2:10]3)=[N:15][C:16]=2[CH:28]=1
ParticipantsConditionsProcedureWorkupSources & evidenceReaction notes

Participants

6

Reactant 3

HCID 7870Hexylene GlycolHCID 27239391,3-Propanediamine, N'-(ethylcarbonimidoyl)-N,N-dimethyl-, monohydrochlorideHCID 59822173(s)-2-(1-(Tert-butoxycarbonyl)-4-(8-chlorodibenzo[b,f][1,4]oxazepin-11-yl)piperazin-2-yl)acetic acid

Product 1

HCID 59822183(s)-Tert-butyl 4-((e)-8-chlorodibenzo[b,f][1,4]oxazepin-11-yl)-2-(2-((r)-4-hydroxy-4-methylpentan-2-yloxy)-2-oxoethyl)piperazine-1-carboxylate

Reagents, catalysts & solvents

2
HCID 142844-(Dimethylamino)pyridineCatalystHCID 6228DimethylformamideSolvent

Conditions

Temperature
50 °C

Procedure

(S,E)-2-(1-(tert-butoxycarbonyl)-4-(8-chlorodibenzo[b,f][1,4]oxazepin-11-yl)piperazin-2-yl)acetic acid (300 mg, 0.60 mmol) can be dissolved in DMF (0.25M). 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.9 mmol), and 4-Dimethylaminopyridine (0.3 mmol) may be added respectively at room temperature under nitrogen. After about fifteen minutes R-(−)-2-Methyl-2,4-pentanediol (0.60 mmol) may be added and the mixture heated to about 50° C. under nitrogen. The product can be worked up as usual and purified by flash chromatography using 10% Acetone/Dichloromethane as the eluent to give (S)-tert-butyl 4-((E)-8-chlorodibenzo[b,f][1,4]oxazepin-11-yl)-2-(2-((R)-4-hydroxy-4-methylpentan-2-yloxy)-2-oxoethyl)piperazine-1-carboxylate as a white foam. The (S)-tert-butyl 4-((E)-8-chlorodibenzo[b,f][1,4]oxazepin-11-yl)-2-(2-((R)-4-hydroxy-4-methylpentan-2-yloxy)-2-oxoethyl)piperazine-1-carboxylate may be dissolved in anhydrous THF and cooled in a dry ice acetone bath under nitrogen. A 2.0M solution of Butyl lithium in cyclohexane (about 1 mole equivalent) may be added dropwise under nitrogen. After about 15 minutes, iodomethane (about 1 mole equivalent) may be added dropwise under nitrogen. After about one hour, a 2.0M solution of Butyl lithium in cyclohexane (about 1 equivalent) may be added dropwise under nitrogen. After about 15 minutes, iodomethane (about 1 equivalent) may be added dropwise under nitrogen. After about one hour the solution may be concentrated under vacuum to give (S)-tert-butyl 4-((E)-8-chlorodibenzo[b,f][1,4]oxazepin-11-yl)-2-(1-((R)-4-hydroxy-4-methylpentan-2-yloxy)-2-methyl-1-oxopropan-2-yl)piperazine-1-carboxylate as a white foam. The (S)-tert-butyl 4-((E)-8-chlorodibenzo[b,f][1,4]oxazepin-11-yl)-2-(1-((R)-4-hydroxy-4-methylpentan-2-yloxy)-2-methyl-1-oxopropan-2-yl)piperazine-1-carboxylate may be dissolved in dichloromethane (about 1.1 ml) and cooled in an ice bath. Trifluoroacetic acid (about 0.5 ml) may be added dropwise under nitrogen and slowly allowed to reach room temperature while running overnight. The mixture may be concentrated under vacuum and purified by flash chromatography using 10% Acetone/Dichloromethane as the eluent to give Compound EK.

Workup

  1. custompurified by flash chromatography

Sources & evidence

ORD record
ord-03f6c8bf27fb43ed93feb0c7bf7cf857
Source dataset
uspto-grants-2012_01
DOI
10.6084/m9.figshare.5104873.v1
Patent number
US08093237B2

Reaction notes

Loading…

On this pageParticipantsConditionsProcedureWorkupSources & evidenceReaction notes